Eli Lilly on Wednesday said its experimental pill led to more weight loss and better control of blood sugar in patients with ...

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Rybelsus becomes the first oral glucagon-like peptide-1 receptor agonist in the EU with proven cardiovascular benefits.

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...

Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.

In a late-stage trial, an investigational GLP-1 pill from Eli Lilly helped diabetes patients lower their blood sugar and ...

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, ...

Rybelsus is approved to treat type 2 diabetes but can now officially list its heart benefits as well.

Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk ...

Novo Nordisk shares are trading higher Monday after the company announced European Union approval for oral semaglutide to ...

The data in non-diabetic subjects with obesity (a body mass index of 30 or more) reveal that patients on a 6 mg daily dose of ...